AKT1 Antibodies

Structure of AKT1

AKT1 is a serine/threonine protein kinase with a molecular weight of approximately 57 kDa, and its molecular weight varies slightly among different species due to sequence differences.

This protein is composed of approximately 480 amino acids, and its three-dimensional structure contains a characteristic PH domain and a kinase domain. After the activation loop (T-loop) in the kinase domain is phosphorylated at the Thr308 and Ser473 sites, the enzyme is fully activated, thereby regulating the downstream signaling pathways. This structural mechanism plays a core regulatory role in the survival, proliferation and metabolic processes of cells.

Fig. 1 Expression of AKT isoforms and experimental strategy.¹

Key structural properties of AKT1:

• Conserved protein kinase structure consisting of a PH domain and a kinase domain
• Regulation of kinase activity dependent on phosphorylation (Thr308/Ser473)
• Substrate recognition and catalytic functions are achieved through ATP-binding pockets

Functions of AKT1

The core function of the AKT1 gene is to regulate cell survival, proliferation and metabolism. In addition, it is also widely involved in multiple physiological and pathological processes such as glycogen synthesis, apoptosis inhibition and angiogenesis.

The activation of AKT1 depends on the phosphatidylinositol 3-kinase (PI3K) signaling pathway, and its activity is strictly regulated by phosphorylation at the Thr308 and Ser473 sites, demonstrating rapid and highly sensitive signal response characteristics and playing a core hub role in cell growth and metabolism.

Applications of AKT1 and AKT1 Antibody in Literature

1. Tian, Xueli, et al. "Costunolide is a dual inhibitor of MEK1 and AKT1/2 that overcomes osimertinib resistance in lung cancer." Molecular Cancer 21.1 (2022): 193. https://doi.org/10.1186/s12943-022-01662-1

This study discovered through phosphorylated proteomics that AKT1/2 was abnormally activated in osimertinib-resistant cells. Computational screening revealed that xylinolide can inhibit AKT1/2 kinase activity. Combined with osimertinib, it synergistically inhibits tumor growth in drug-resistant models, providing a potential therapeutic strategy for overcoming EGFR-TKI resistance.

2. George, Bijesh, et al. "AKT1 transcriptomic landscape in breast cancer cells." Cells 11.15 (2022): 2290. https://doi.org/10.3390/cells11152290

This study found through RNA sequencing that AKT1 not only positively regulates gene expression in breast cancer cells but also unexpectedly inhibits the transcription of some genes. After knockdown or inhibition of AKT1, these genes were significantly upregulated and consistent in clinical samples, expanding the understanding of the transcriptional regulatory function of AKT1.

3. Frederick, Mallory I., et al. "miRNA-dependent regulation of AKT1 phosphorylation." Cells 11.5 (2022): 821. https://doi.org/10.3390/cells11050821

This study found that in ovarian cancer, the let-7 miRNA family regulates molecules such as PI3KC2A, PDK1 and RICTOR, alters the phosphorylation patterns at the AKT1 T308 and S473 sites, affects their activity and downstream signals, and reveals a new mechanism by which miRNA regulates the AKT pathway.

4. Siddika, Tarana, et al. "Delivery of active AKT1 to human cells." Cells 11.23 (2022): 3834. https://doi.org/10.3390/cells11233834

This study developed a novel TAT-tag fused AKT1 protein delivery system, which can efficiently introduce active AKT1 with specific phosphorylation modifications into human cells without transfection reagents and continuously act for 24 hours, providing a new tool for studying AKT1-specific signal transduction.

5. Guirouilh-Barbat, Josée, Therese Wilhelm, and Bernard S. Lopez. "AKT1/BRCA1 in the control of homologous recombination and genetic stability: the missing link between hereditary and sporadic breast cancers." Oncotarget 1.8 (2010): 691. https://doi.org/10.18632/oncotarget.203

Research has found that AKT1 is closely related to DNA damage response (DDR) and homologous recombination (HR) repair in breast cancer. Excessive activation of AKT1 can inhibit the functions of BRCA1 and HR, but under physiological conditions, it may prevent excessive HR through moderate regulation to maintain genomic stability.

Creative Biolabs: AKT1 Antibodies for Research

Creative Biolabs specializes in the production of high-quality AKT1 antibodies for research and industrial applications. Our portfolio includes monoclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom AKT1 Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our AKT1 antibodies, custom preparations, or technical support, contact us at email.